Pherecydes Pharma and BIOASTER join forces in the treatment of bacteremia

(Boursier.com) — Pherecydes Pharmaa biotechnology company specializing in precision phage therapy intended to treat resistant and/or complicated bacterial infections, and BIOASTER, the first Institute for Technological Innovation in Microbiology, today announce the establishment of a research collaboration to treat bacteraemia (blood infections) caused by the bacteria S. aureus, E. Coli and Pseudomonas aeruginosa with phages.

Bacteremia, defined as the presence of pathogenic bacteria in the circulating blood, represents the second cause of bacterial infection in the world with approximately 1.5 million deaths associated with this pathology per year. In the United States alone, the CDC estimates that up to 1.7 million people develop bacteremia each year. S. aureus is the most commonly identified pathogen, both in hospital settings and in the community. Age-adjusted mortality estimates show that mortality from S. aureus bacteremia is higher than that from AIDS, tuberculosis, or viral hepatitis, and comparable to mortality rates from breast cancer or prostate. E. Coli and Pseudomonas aeruginosa are also major causes of antibiotic-resistant bacteremia.

As part of this collaboration, Pherecydes Pharma will rely on BIOASTER’s excellence in the development of relevant preclinical models for these infections in order to test the effectiveness of the proprietary phages selected by Pherecydes Pharma on these pathologies.

Guy-Charles Fanneau de La Horie, Chairman of the Management Board of Pherecydes Pharma, declares: “We are very pleased to launch this new research program which is part of a broader partnership that we are developing with BIOASTER, an institute whose excellence is recognized worldwide. In fact, bacteremia represents major new applications for the development of our anti-S. aureus, Pseudomonas aeruginosa and E. Coli phages. The in-vivo demonstrations that we are expecting thanks to this collaboration may eventually open up new markets with very significant commercial potential. This collaboration is part of the strategy implemented by the Company which aims to broaden the fields of application of existing assets.”

–

©2022 Boursier.com

–